349 related articles for article (PubMed ID: 9028553)
1. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
Takenaka K; Gondo H; Tanimoto K; Nagafuji K; Fujisaki T; Mizuno S; Miyamoto T; Okamura T; Hayashi S; Eto T; Osaki K; Yamasaki K; Shibuya T; Harada N; Teshima T; Matsuishi E; Minematsu T; Minamishima Y; Harada M; Niho Y
Bone Marrow Transplant; 1997 Feb; 19(3):241-8. PubMed ID: 9028553
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
[TBL] [Abstract][Full Text] [Related]
3. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
Shimokawa T; Morishima Y; Kitaori K; Kato C; Sao H
Int J Hematol; 1999 Aug; 70(2):119-26. PubMed ID: 10497851
[TBL] [Abstract][Full Text] [Related]
4. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality.
Bacigalupo A; Tedone E; Isaza A; Soracco M; Van Lint MT; Sanna A; Frassoni F; Occhini D; Gualandi F; Lamparelli T
Bone Marrow Transplant; 1995 Jul; 16(1):155-61. PubMed ID: 7581116
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
[TBL] [Abstract][Full Text] [Related]
6. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
[TBL] [Abstract][Full Text] [Related]
8. Surveillance of cytomegalovirus infections in bone marrow transplant in Trieste: seven years' experience.
D'Agaro P; Andolina M; Burgnich P; Samar E; Campello C
Haematologica; 2000 Nov; 85(11 Suppl):54-7. PubMed ID: 11268325
[TBL] [Abstract][Full Text] [Related]
9. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
[TBL] [Abstract][Full Text] [Related]
10. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection.
Kim DH; Kim JG; Lee NY; Sung WJ; Sohn SK; Suh JS; Lee KS; Lee KB
Bone Marrow Transplant; 2004 Jul; 34(1):21-7. PubMed ID: 15133483
[TBL] [Abstract][Full Text] [Related]
13. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
[TBL] [Abstract][Full Text] [Related]
15. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus.
Mikulska M; Raiola AM; Bruzzi P; Varaldo R; Annunziata S; Lamparelli T; Frassoni F; Tedone E; Galano B; Bacigalupo A; Viscoli C
Biol Blood Marrow Transplant; 2012 Jan; 18(1):92-9. PubMed ID: 21689774
[TBL] [Abstract][Full Text] [Related]
16. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
17. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections.
Bacigalupo A; Tedone E; Van Lint MT; Trespi G; Lonngren M; Sanna MA; Moro F; Frassoni F; Occhini D; Gualandi F
Bone Marrow Transplant; 1994 Jun; 13(6):783-8. PubMed ID: 7920315
[TBL] [Abstract][Full Text] [Related]
18. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
19. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
[TBL] [Abstract][Full Text] [Related]
20. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality.
Bacigalupo A; Tedone E; Sanna MA; Moro F; Van Lint MT; Grazi G; Balestreri M; Frassoni F; Occhini D; Gualandi F
Haematologica; 1992; 77(6):507-13. PubMed ID: 1337746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
